The Latest

In the ever-evolving world of healthcare, innovation is key to delivering exceptional patient care. RegenMed is at the forefront of this revolution, providing physicians with turnkey solutions that streamline processes and enhance outcomes. But how exactly does RegenMed empower physicians? Seamless Integration: RegenMed offers comprehensive solutions that integrate seamlessly into existing workflows, reducing administrative burdens and allowing physicians to focus on what they do best — caring for patients. Cutting-Edge Technology: With advanced tools and technologies, RegenMed enables physicians to stay ahead of the curve, providing the latest treatments and therapies to their patients. Enhanced Patient Outcomes: By leveraging data-driven insights and innovative treatments, RegenMed helps physicians achieve better patient outcomes, improving overall health and well-being. Cost Efficiency: Turnkey solutions from RegenMed are designed to be cost-effective, helping practices manage resources more efficiently without compromising on quality. Continuous Support: RegenMed provides ongoing support and training, ensuring that physicians are always equipped with the knowledge and tools they need to succeed. At RegenMed, we understand the transformative power of Circles. Our platform connects physicians with these innovative solutions, empowering them to deliver the best possible care. Learn more how it works: Physician-Owned Circles (POC) - How It Works

From the CEO2025 promises to be an exciting year for RegenMed. We are welcoming new clients, who will be using Circles to make a real difference in evidence-based healthcare for more people.We have strengthened our senior IT leadership, as we architect Circles 4.0. The Company's Strategic Plan incorporates recursive Al learning from Circles databases, as well as blockchain/tokenization for longitudinal medical records.Our Physicians-Owned Circles are proving to be a major step forward in returning to doctors the value created by their clinical hypotheses and data.RegenMed is in a strong position to disrupt a healthcare data market which is delivering too little clinical value for too few people.Please keep with us on our Latest page. Write to us; we love to hear from our shareholders and our clients - including our future ones.Client NewsDr. Marcus Klingenberg, an internationally recognized orthopedic surgeon, will be acting as a Principal Investigator for four separate Physicians-Owned Circles in the field of micronized adipose tissue therapies for musculoskeletal indications. See more here.We have contracted with a publicly traded biotechnology company to support an open-label, IRB-monitored, clinical trial covering exosome therapy in patients suffering from joint and spine pathologies. Follow our Latest page for more details soon, including investigator recruitment.RegenMed will be partnering with a major U.S. foundation to implement a series of Physicians-Owned Circles for orthopedic, biologies and other musculoskeletal indications. These will cover common pathologies and treatment protocols, as well as rare MSK diseases (such as osteogenesis imperfecta and spinal muscular atrophy.)We look forward to providing more details in the weeks to come.Strengthening Our Information And Technology TeamThe Company is fortunate to have Ms. Laura Prey join as a corporate board member, and Mr. Dolph Courchaine assume the role of Chief Technology and Information Officer. They combine decades of IT design and management experience at some of the largest healthcare providers and insurers in the country.Their guidance is already proving crucial as we prepare the advanced platform architecture and then implementation plan for "Circles 4.0".Physicians-Owned CirclesThe most valuable healthcare data sets are those generated directly by physicians, sharing a common clinical hypothesis and patient cohort.Each POC develops clinically and statistically significant data sets based on a specific anatomical region, pathology, treatment, protocol, and outcomes assessment.POCs are 85% owned by participating physicians, who receive a corresponding percentage of license fees. See here for more information.New WebsiteWe hope you will enjoy our new website. In addition to describing our offerings and value propositions more clearly, it provides a single point of entry for all healthcare constituencies to see how Circles work.Our expanding library of Physicians-Owned Circles is supplemented by a similarly growing library of Private Circles, which may be joined upon Sponsor approval.Our Latest page contains a regularly updated list of white papers, articles, and client news.Stay Tuned...In addition to updates on existing and new clients, upcoming newsletters will provide an overview of our 2025 Strategic Plan, capital-raising initiatives. Circle Hours for POC Members, channel partners, and other items of interest to shareholders and the healthcare community at large.‍

Executive SummaryOsteogenesis imperfecta (OI) presents lifelong clinical challenges for patients and physicians alike — from managing fracture risk to navigating bisphosphonate therapy and surgical interventions. Yet few providers have access to longitudinal, structured outcome data to guide treatment decisions or assess long-term effectiveness.RegenMed Circles changes that by giving physicians the tools to collect compliant, real-world data (RWD) directly from clinical care — without disrupting workflows. With Circles, OI specialists gain insights that lead to better protocols, stronger patient outcomes, and evidence-based care pathways tailored to rare bone disease.While Circles support revenue generation through data licensing, the core mission remains clinical: empowering communities of providers to advance care through shared data, shared insights, and shared impact.IntroductionOsteogenesis imperfecta (OI) is a rare genetic disorder characterized by increased bone fragility, which often requires a lifetime of complex care. Patients with OI may receive bisphosphonate infusions to improve bone density, undergo corrective surgeries to manage fractures or deformities, or benefit from physical therapy and emerging regenerative approaches. However, despite advancements in medical treatments, clinicians continue to face significant uncertainty in managing OI.Questions persist about which patients respond best to bisphosphonates over time, how fracture frequency may change with growth or puberty, and what the long-term functional outcomes are of early orthopedic interventions. These critical issues are difficult to answer with certainty, and many providers must rely on fragmented notes, anecdotal recall, or small, siloed studies to inform their high-stakes decisions. In a field where treatment protocols and patient care are still evolving, it’s clear that the need for better, more structured data has never been greater.The Opportunity: Closing The Outcomes GapOI care spans years, disciplines, and interventions — but structured outcome tracking is virtually nonexistent. Physicians often struggle to:Standardize assessments of pain, function, and quality of lifeTrack treatment response across growth stagesAnalyze long-term effects of pharmacologic and surgical interventionsShare data or collaborate with peers on new protocolsThis creates missed opportunities to learn from real-world outcomes and improve care at scale. As precision medicine advances and regulators seek more real-world evidence, longitudinal, de-identified datasets are becoming critical — not optional.‍Regenmed Circles: A Platform For Collaborative CareRegenMed Circles are secure, physician-led networks built to collect, analyze, and share structured outcome data — designed specifically for rare and complex conditions like OI.Through Circles, OI providers can:Capture patient-reported outcomes and clinical events across visitsTrack response to bisphosphonate therapy, surgeries, and rehab over timeCompare anonymized data against aggregate benchmarksPropose or join disease-specific registries and research cohortsEach Circle is tailored to clinical priorities — like fracture incidence, mobility scores, or growth metrics — and can incorporate custom scoring formulas and patient-reported outcome measures (PROMs) built in collaboration with care teams.Physicians can join existing Circles or propose new ones based on their areas of interest.Real-world evidence is becoming essential — not optional.Improving Patient Outcomes Through Real-World EvidenceBy collecting outcomes data in a structured, longitudinal format, clinics gain powerful tools to improve care:Identify top-performing protocols and refine treatment plansMonitor long-term changes in mobility, function, and painDetect adverse events early and respond proactivelyShare findings with peers, researchers, and familiesCircle members receive interactive dashboards, cohort-level reports, and access to collaborative datasets.These tools empower providers to continuously improve outcomes — without hiring new staff or disrupting care delivery. See below for some examples of what the platform looks like and how it can be used to assess patient outcomes.‍Monetizing Your Real-World DataIn addition to improving care, RegenMed Circles create sustainable revenue through compliant, de-identified data licensing. Clinics can:License aggregate datasets to pharma, device, or digital health partnersEarn up to 85% of licensing revenueParticipate in studies that shape future treatment developmentRevenue is just the beginning. Circle participation supports scientific publications, conference presentations, and national recognition for clinical leadership.Call To ActionWhether you specialize in pediatric bone health, genetic orthopedics, or multidisciplinary rare disease care, RegenMed Circles can help you turn everyday care into evidence-based advancement.Visit www.rgnmed.com/circles or contact us to learn how to launch or join an OI Circle tailored to your clinical priorities.‍

Executive SummarySMA treatment is rapidly evolving, providing patients with increasing therapeutic options. However, challenges remain in consistently measuring treatment outcomes and facilitating real-time collaboration among clinicians. RegenMed Circles offer SMA specialists a platform to collect standardized, compliant real-world data (RWD) from routine clinical practice. The goal is to generate deeper insights, refine treatment strategies, and ultimately improve outcomes for every individual with SMA.While potential for data sharing exists, the central aim of RegenMed Circles is to foster clinician-led communities dedicated to accelerating advancements in SMA treatment and promoting clinical excellence. By participating, clinicians can enhance patient care while benefiting from comprehensive benchmarking tools, peer collaboration, and opportunities for professional development.IntroductionThe spinal muscular atrophy (SMA) treatment landscape has been revolutionized in recent years. From gene therapies and antisense oligonucleotides to small molecule SMN protein enhancers, clinicians now have more therapeutic options available than ever before. However, despite these significant clinical advancements, the infrastructure to systematically collect meaningful, comparative outcome data across these diverse treatments often lags behind.This limitation hinders the ability of clinicians and researchers to optimize treatment protocols, benchmark effectiveness across different interventions, and contribute robust data to the broader understanding of long-term outcomes in SMA. RegenMed Circles was established to address this critical need — providing a platform for the SMA community to seamlessly track and analyze patient outcomes at scale.The Opportunity: Closing The Outcomes GapSMA care is increasingly outcome-focused, yet few treatment centers possess real-time, structured insights into their own performance, much less how it compares to others. SMA care teams often face challenges in:Standardize outcome tracking across providers and protocolsAnalyze trends over time or across treatment typesFacilitating knowledge sharing and collaboration on clinical advancements within the SMA communityAs individuals with SMA and their families become more informed about outcomes and as payers increasingly require robust data, the necessity for structured, real-world evidence is becoming fundamental — not optional. We can build your Circle based on your preference of outcomes measurements through the creation of Scoring Formulas, like the ones pictured below, to help you identify treatment outcome trends in SMA.Regenmed Circles: A Platform For Collaborative CareRegenMed Circles are secure, collaborative networks that enable clinics to:Collect and structure real-world treatment outcomes with zero workflow disruptionCompare anonymized results with national benchmarksCollaborate with peers on protocols, research, and publicationsKeep full ownership and control of their patient dataEach Circle focuses on a specific treatment domain or outcome type. Physicians can join existing Circles or propose new ones based on their areas of interest.Real-world evidence is becoming essential — not optional.Improving Patient Outcomes Through Real-World EvidenceBy collecting outcomes data in a structured, longitudinal format, clinics gain powerful tools to improve care:Identify top-performing protocols and refine treatment plansEnhance cycle prep strategies and optimize timingShare de-identified insights across clinical teamsTrack long-term patient success — not just short-term metricsCircle members receive interactive dashboards, cohort-level reports, and access to collaborative datasets.These tools empower SMA providers to continuously improve outcomes — without hiring new staff or disrupting care delivery. See below for some examples of what the platform looks like and how it can be used to assess patient outcomes.Monetizing Your Real-World DataIn addition to improving care, RegenMed Circles create sustainable revenue through compliant, de-identified data licensing. Clinics can:License aggregate datasets to pharma, device, or digital health partnersEarn up to 85% of licensing revenueParticipate in studies that shape future treatment developmentRevenue is just the beginning. Circle participation supports scientific publications, conference presentations, and national recognition for clinical leadership.Call To ActionCircles give doctors treating Spinal Muscular Atrophy a powerful way to elevate care and lead innovation. Whether you're optimizing supportive care protocols, or working with disease-modifying therapies — Circles make your outcomes work for you.Join a growing network of physician-led innovators who are shaping the future of SMA care with real-world evidence.Visit www.rgnmed.com/circles or contact us to learn how to join or launch your own Circle.

Executive SummaryCystic fibrosis (CF) is a complex, multisystem condition driven by mutations in the CFTR gene. While CFTR modulators have transformed care for many, a significant subset of patients — particularly those with rare or unresponsive mutations — remain underserved. Even for those benefiting from new therapies, the ability to measure long-term effectiveness, collaborate across sites, and adapt protocols based on real-world outcomes remains limited.RegenMed Circles addresses these challenges by enabling CF physicians to collect structured, standardized, and HIPAA-compliant real-world data (RWD) directly from clinical care. This data fuels continuous improvement in treatment, supports innovation in research, and enables new revenue through data licensing. The result? Better insights, better care, and faster progress — for every person with CF.IntroductionThe CF care landscape is undergoing rapid change. With the widespread use of CFTR modulators and expanding pipelines in gene and mRNA therapy, care teams have more options than ever. Yet most CF clinics lack infrastructure to track outcomes across time, measure treatment durability, or collaborate on emerging therapies in real time.RegenMed Circles was built to close that gap — giving CF clinicians a scalable, seamless way to collect, benchmark, and act on clinical outcome data, while also participating in studies that help advance future treatments.The Opportunity: Closing The Outcomes GapCF is increasingly outcome-driven, but many clinicians still face key barriers to turning clinical observations into actionable data:Inconsistent tracking of outcomes like FEV1 change, exacerbation frequency, nutritional status, or mental health indicatorsLimited ability to benchmark patient trajectories against peers nationally or globallyMinimal infrastructure for contributing to collaborative research or post-market surveillanceAs patient needs evolve and research accelerates, structured RWD is no longer optional —it’s essential to unlocking the next phase of CF innovation. Here at RegenMed, we can build your Circle based on your preference of outcomes measurements through the creation of Scoring Formulas, like the ones pictured below, to help you identify treatment outcome trends.‍Regenmed Circles: A Platform For Collaborative CareRegenMed Circles offer secure, physician-led networks designed to:Capture and structure longitudinal CF data with zero disruption to workflowBenchmark individual patient outcomes against broader cohortsSupport collaboration across clinics on emerging therapies, protocols, and real-world validationMaintain full data ownership for clinicians and their institutionsEach Circle centers around a specific CF treatment focus or outcome type. Examples include:Longitudinal tracking of CFTR modulator effectiveness by mutation groupNutritional outcomes (BMI, weight gain) in pediatric and adult CFUse of gene or mRNA therapies in patients with rare genotypesFrequency and severity of pulmonary exacerbationsMental health and quality-of-life tracking in chronic CF carePhysicians can join existing Circles or propose new ones tailored to the populations they serve or therapies they wish to explore.Improving Patient Outcomes Through Real-World EvidenceWith structured RWD, CF care teams can:Refine protocols based on mutation-specific response patternsDetect early signs of treatment decline or breakthrough infectionAdapt care delivery based on long-term patient trendsIdentify subgroups most likely to benefit from emerging therapiesCollaborate with peers to publish findings and influence standards of careCircle members receive cohort-level reports, dashboards, and access to de-identified collaborative datasets. No additional staff or technical infrastructure is required — just better insights from the care you’re already providing.Monetizing Your Real-World DataIn addition to supporting clinical excellence, RegenMed Circles offer sustainable, physician-led revenue models:License de-identified datasets to pharma, biotech, and digital health partnersEarn up to 85% of data licensing revenueParticipate in industry-sponsored studies and registry collaborationsUse funds to reinvest in research, care delivery, or new technologiesParticipation also builds a foundation for peer-reviewed publications, conference abstracts, and clinical leadership in the rare disease space.Call To ActionCystic Fibrosis care is evolving — and your data can help lead the way. Whether you're evaluating CFTR modulators, preparing for gene therapy trials, or simply working to understand long-term outcomes in your patients, RegenMed Circles empowers you to track, collaborate, and innovate.Join a physician-led network that's redefining how we measure success in cystic fibrosis — one dataset at a time.Visit www.rgnmed.com/circles or contact us to learn how to join or launch your own Circle.